Assessment of bevacizumab conjugated to Cy5.5 for detection of head and neck cancer xenografts

Technology in Cancer Research and Treatment

Volumn 7, Issue 1, 2008, Pages 61-66

  Withrow, Kirk P ^a   Newman, J Robert ^a   Skipper, Joni B ^a   Gleysteen, John P ^a   Magnuson, J Scott ^a   Zinn, Kurt ^b   Rosenthal, Eben L ^a  

^a Kentucky   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CY5 5 DYE; CYDYE; DEOXYRIBONUCLEOTIDE; FLUORESCENT DYE; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONJUGATE; CONJUGATION; CONTRAST; CONTROLLED STUDY; CORRELATION ANALYSIS; FLUORESCENCE; HEAD CANCER; HISTOPATHOLOGY; MOUSE; NECK CANCER; NONHUMAN; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; STEREOMICROSCOPY; TUMOR BIOPSY; TUMOR CELL; XENOGRAFT;

EID: 39049125272     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460800700108     Document Type: Article

References (30)

1. McMahon, J., O'Brien, C. J., Pathak, I., et al. Influence of condition of surgical margins on local recurrence and disease-specific survival in oral and oropharyngeal cancer. Br J Oral Maxillofac Surg 41, 224-231 (2003).
2. Ravasz, L. A., Slootweg, P. J., Hordijk, G. J., Smit, F., van der Tweel, I. The status of the resection margin as a prognostic factor in the treatment of head and neck carcinoma. J Craniomaxillofac Surg 19, 314-318 (1991).
3. Bouvet, M., Spernyak ,J., Katz, M. H., et al. High correlation of whole-body red fluorescent protein imaging and magnetic resonance imaging on an orthotopic model of pancreatic cancer. Cancer Res 65, 9829-9833 (2005).
4. Chen, Y., Intes, X., Chance, B. Development of high-sensitivity near-infrared fluorescence imaging device for early cancer detection. Biomed Instrum Technol 39, 75-85 (2005).
5. Citrin, D., Lee, A. K., Scott, T., et al. In vivo tumor imaging in mice with near-infrared labeled endostatin. Mol Cancer Ther 3, 481-488 (2004).
6. Citrin, D., Scott, T., Sproull, M., Menard, C., Tofilon, P. J., Camphausen, K. In vivo tumor imaging using a near-infrared-labeled endostatin molecule. Int J Radiat Oncol Biol Phys 58, 536-541 (2004).
7. Hama, Y., Urano, Y., Koyama, Y., et al. In vivo spectral fluorescence imaging of submillimeter peritoneal cancer implants using a lectin-targeted optical agent. Neoplasia 8, 607-612 (2006).
8. Soltesz, E. G., Kim, S., Kim, S. W., et al. Sentinel lymph node mapping of the gastrointestinal tract by using invisible light. Ann Surg Oncol 13, 386-396 (2006).
9. Parungo, C. P., Colson, Y. L., Kim, S. W., et al. Sentinel lymph node mapping of the pleural space. Chest 127, 1799-1804 (2005).
10. Rosenthal, E. L., Kulbersh, B. D., Duncan, R. D., et al. In vivo detection of head and neck cancer orthotopic xenografts by immunofluorescence. Laryngoscope 116, 1636-1641 (2006).
11. Spaulding, D. C., Spaulding, B. O. Epidermal growth factor receptor expression and measurement in solid tumors. Semin Oncol 29, 45-54 (2002).
12. Bonner, J. A., De Los Santos, J., Waksal, H. W., Needle, M. N., Trammel, H. Q., Raisch, K. P. Epidermal growth factor receptor as a therapeutic target in head and neck cancer. Semin Radiat Oncol 12, 11-20 (2002).
13. Ferrara, N. VEGF as a therapeutic target in cancer. Oncology 69, 11-16 (2005).
14. Kostler, W. J., Brodowicz, T., Hudelist, G., et al. The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status. J Cancer Res Clin Oncol 131, 420-428 (2005).
15. Lim, S. C. Expression of c-erbB receptors, MMPs and VEGF in head and neck squamous cell carcinoma. Biomed Pharmacother 59, S366-369 (2005).
16. Ueno, Y. (Implication of vascular endothelial growth factor (VEGF) in human head and neck cancer). Nippon Jibiinkoka Gakkai Kaiho 109, 163-170 (2006).
17. Soh, E. Y., Duh, Q. Y., Sobhi, S. A., et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 82, 3741-3747 (1997).
18. Neufeld, G., Cohen, T., Gengrinovitch, S., Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. Faseb J 13, 9-22 (1999).
19. Kyzas, P. A., Stefanou, D., Batistatou, A., Agnantis, N. J. Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol 131, 624-630 (2005).
20. Thomas, G. R., Nadiminti, H., Regalado, J. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol 86, 347-363 (2005).
21. Tse, G. M., Chan, A. W., Yu, K. H., et al. Strong immunohistochemical expression of vascular endothelial growth factor predicts overall survival in head and neck squamous cell carcinoma. Ann Surg Oncol 14, 3558-3565 (2007).
22. Ide, M. Cancer screening with FDG-PET. Q J Nucl Med Mol Imaging 50, 23-27 (2006).
23. Liang, W. C., Wu, X., Peale, F. V., et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contributions of stromal VEGF. J Biol Chem 281, 951-961 (2006).
24. Achilefu, S., Dorshow, R. B., Bugaj, J. E., Rajagopalan, R. Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging. Invest Radiol 35, 479-485 (2000).
25. Ye, Y., Bloch, S., Kao, J., Achilefu, S. Multivalent carbocyanine molecular probes: synthesis and applications. Bioconjug Chem 16, 51-61 (2005).
26. Ye, Y., Bloch, S., Xu, B., Achilefu, S. Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem 49, 2268-2275 (2006).
27. Tokunaga, E., Oki, E., Nishida, K., et al. Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol 11, 199-208 (2006).
28. Booy, E. P., Johar, D, Maddika, S., et al. Monoclonal and bispecific antibodies as novel therapeutics. Arch Immunol Ther Exp (Warsz). Mar 24 2006.
29. Gambill, B. D. Edrecolomab (Panorex) as adjuvant therapy for stage II colon cancer. Clin Colorectal Cancer 1, 16-17 (2001).
30. Harris, M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 5, 292-302 (2004).